|Dr. Avtar S. Dhillon||Exec. Chairman||485.05k||N/A||1962|
|Mr. Riaz Bandali M.B.A.||CEO & Pres||428.21k||N/A||1970|
|Ms. Jenn Hepburn B.B.A.||CFO & Company Sec.||952.84k||N/A||N/A|
|Mr. Orville Bovenschen||Sr. VP of Operations||N/A||N/A||N/A|
|Mr. Bernie Hertel||VP of Fin. and Communications||N/A||N/A||N/A|
|Ms. Rebecca Wong||Sr. VP of Quality & Regulatory Affairs||N/A||N/A||N/A|
Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.
Emerald Health Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.